Comparable stake leader
David E. Lazar
SEC ownership of Indaptus Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001857044.
Disclosed value leader
Yun Yao
Comparable rows
7/30
Latest evidence
24 Jun 2026
- Public ticker
- INDP on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
David E. Lazar
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
7 of 30
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
David E. Lazar
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
24 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001857044
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Indaptus Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
David E. Lazar
Disclosed value leader
Yun Yao
Comparable rows
7/30
Latest evidence
24 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 48%
23 rows are not safely comparable across share classes.
13D/G row: David E. Lazar
Showing 1-8 of 30 holder rows.
Quick read
David E. Lazar leads the comparable SEC ownership view at 48%.
7 of 30 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens David E. Lazar's linked filing trail.
Comparable ownership
Top 5
David E. Lazar
48%
Yun Yao
32%
SINO LION VENTURES Ltd
29%
Jeffrey A. Meckler
13%
Junyi Dai
8.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 30 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| David E. Lazar |
13D/G
3/4/5
Lazar David E. · Director
|
48%
|
$949,440
2,064,000 shares
|
-$50,110,560 | 23 Mar 2026 |
| Yun Yao |
3/4/5
13D/G
10%+ Owner · Yao Yun
|
32%
from 13D/G
|
$122,189,610
41,991,000 shares
|
— | 23 Mar 2026 |
| SINO LION VENTURES Ltd |
3/4/5
13D/G
10%+ Owner
|
29%
from 13D/G
|
$113,180,560
38,895,000 shares
|
— | 23 Mar 2026 |
| Jeffrey A. Meckler |
3/4/5
13D/G
Co-Chief Executive Officer, Director · Jeffery A. Meckler
|
13%
from 13D/G
|
$605,305
258,753 shares
mixed-class rows
|
— | 11 Feb 2026 |
| Junyi Dai |
3/4/5
13D/G
Chief Executive Officer · Dai Junyi
|
8.4%
from 13D/G
|
$32,736,375
11,250,000 shares
|
— | 23 Mar 2026 |
| Yang Ting |
13D/G
|
8.4%
|
$5,175,000
11,250,000 shares
|
$0 | 24 Jun 2026 |
| Michael James Newman |
3/4/5
13D/G
CSO and Director, Director · Newman Michael James
|
5.4%
from 13D/G
|
$205,180
101,074 shares
|
— | 22 Dec 2025 |
| Glen R. Anderson |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$2,785,536
1,190,400 shares
|
— | 10 Aug 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Indaptus Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Yun Yao
Net 12M change
$0
Latest report
08 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Yun Yao | 10%+ Owner | $122,189,610 | Mixed | 23 Mar 2026 | ||
| SINO LION VENTURES Ltd | 10%+ Owner | $113,180,560 | Mixed | 23 Mar 2026 | ||
| Junyi Dai | Chief Executive Officer | $32,736,375 | Mixed | 23 Mar 2026 | ||
| Glen R. Anderson | 10%+ Owner | $2,785,536 | Filing P/S | 10 Aug 2023 | ||
| Hoonmo Lee | Director | $1,626,157 | Mixed | 04 Aug 2021 | ||
| Jeffrey A. Meckler | Co-Chief Executive Officer, Director | $605,305 | Mixed | 11 Feb 2026 | ||
| Michael James Newman | CSO and Director, Director | $205,180 | Mixed | 22 Dec 2025 | ||
| Walt Addison Linscott | Chief Operating Officer | $110,484 | Mixed | 22 Dec 2025 | ||
| Avraham Ben-Tzvi | Director | $68,272 | Mixed | 23 Dec 2025 | ||
| Matthew Charles McMurdo | Director | $54,750 | Mixed | 26 Feb 2026 | ||
| Nir Sassi | Chief Financial Officer | $54,318 | Mixed | 22 Dec 2025 | ||
| Roger J. Waltzman | Chief Medical Officer | $5,325 | Mixed | 09 Oct 2024 | ||
| Boyan Vesselinov Litchev | Chief Medical Officer | $2,691 | Mixed | 01 Feb 2022 | ||
| Brian O'Callaghan | Director | $976 | Mixed | 30 Sep 2022 | ||
| Mark J. Gilbert | Director | $888 | Mixed | 10 Jun 2025 | ||
| Robert Martell | Director | $888 | Mixed | 10 Jun 2025 | ||
| David E. Lazar | Director | $0 | Mixed | 23 Mar 2026 | ||
| Hila Karah | Director | $0 | Mixed | 10 Jun 2025 | ||
| Anthony J. Maddaluna | Director | $0 | Mixed | 10 Jun 2025 | ||
| Roger Pomerantz | Director | $0 | Mixed | 10 Jun 2025 |
Recent insider transactions for Indaptus Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David E. Lazar | INDP | Series AAA Convertible Non-Redeemable Preferred Stock | Sale | -100% | -700,000 | 0 | 23 Mar 2026 | Direct | ||
| David E. Lazar | INDP | Series AA Convertible Non-Redeemable Preferred Stock | Sale | -65.6% | -196,800 | 103,200 | 23 Mar 2026 | Direct | ||
| Jerome D. Jabbour | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 26 Feb 2026 | Direct | |||
| Jeffrey A. Meckler | INDP | Warrants (right to buy) | Award | 16,688 | 12,136 | 11 Feb 2026 | Direct | |||
| Jeffrey A. Meckler | INDP | Warrants (right to buy) | Disposed to Issuer | -100% | -16,688 | 0 | 11 Feb 2026 | Direct | ||
| Avraham Ben-Tzvi | INDP | Common Stock | Award | 25000% | 25,000 | 25,100 | 20 Jan 2026 | Direct | ||
| David Natan | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 07 Jan 2026 | Direct | |||
| Avraham Ben-Tzvi | INDP | Option to Buy Common Stock | Award | 25,000 | 25,000 | 23 Dec 2025 | Direct | |||
| Nir Sassi | INDP | Common Stock | Award | 26,758 | 26,758 | 22 Dec 2025 | Direct | |||
| Jeffrey A. Meckler | INDP | Common Stock | Award | 1627.2% | 216,617 | 229,929 | 22 Dec 2025 | Direct | ||
| Michael James Newman | INDP | Common Stock | Award | 106.8% | 52,204 | 101,074 | 22 Dec 2025 | Direct | ||
| Walt Addison Linscott | INDP | Common Stock | Award | 1088420% | 54,421 | 54,426 | 22 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.